Olmesartan reverses not only vascular endothelial dysfunction but cardiac diastolic dysfunction in hypertensive patients with heart failure with preserved ejection fraction — ORION study

摘要

Theoptimaltreatmentforheartfailure(HF)withpreservedleftven-tricular ejection fraction (LVEF) (HFpEF) has not been established [1],because the precise pathophysiological mechanism underlying HFpEFstill remains unclear. Using experimental models of HFpEF, we previ-ously reported a novel mechanism underlying reversal of endothelialdysfunction and HFpEF by antioxidant effects by AT 1 -receptor block-ade [2]. Furthermore, we recently demonstrated the clinical signifi-cance of derivatives of reactive oxidative metabolites (DROM, Diacronsrl, Grosseto, Italy), a novel biomarker of reactive oxygen species(ROS), in HFpEF patients [3]. Hence, by performing this study (ORION:OlmesaRtan Improvement endothelial functiON with hypertensionstudy), we examined the clinical therapeutic effect of AT 1 -receptorblocker (ARB) on HFpEF patients.